@article{3078043,
    title = "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma",
    author = "Weisel, K. and Dimopoulos, M. and Moreau, P. and Yagci, M. and Larocca, A. and Kanate, A.S. and Vural, F. and Cascavilla, N. and Basu, S. and Johnson, P. and Byeff, P. and Hus, M. and Rodríguez-Otero, P. and Muelduer, E. and Anttila, P. and Hayden, P.J. and Krauth, M.-T. and Lucio, P. and Ben-Yehuda, D. and Mendeleeva, L. and Guo, S. and Yu, X. and Grote, L. and Biyukov, T. and Dhanasiri, S. and Richardson, P.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2020",
    volume = "61",
    number = "8",
    pages = "1850-1859",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.1080/10428194.2020.1747066",
    keywords = "bortezomib;  dexamethasone;  lenalidomide;  pomalidomide;  antineoplastic agent;  bortezomib;  dexamethasone;  pomalidomide;  thalidomide, aged;  Article;  cancer recurrence;  clinical outcome;  controlled study;  European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30;  European Quality of Life 5 Dimensions 3 Level questionnaire;  fatigue;  female;  global health;  health status;  human;  intention to treat analysis;  low drug dose;  major clinical study;  male;  multiple cycle treatment;  multiple myeloma;  open study;  post hoc analysis;  priority journal;  qlq my20 questionnaire;  quality of life;  questionnaire;  symptom;  unspecified side effect;  multiple myeloma;  tumor recurrence, Antineoplastic Combined Chemotherapy Protocols;  Bortezomib;  Dexamethasone;  Humans;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Quality of Life;  Thalidomide",
    abstract = "In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM. © 2020 Informa UK Limited, trading as Taylor & Francis Group."
}